Nanobiotix looks to bring cancer treatment to market

May 26, 2014 by Ellen Goldbaum

Laurent Levy left the University at Buffalo in 1999 with a dream: transforming his recently completed postdoctoral research on nanomedicine into real-world products for patients battling cancer.

Today, the scientist-turned-entrepreneur is zeroing in on that goal.

In February, Levy's drug development company, Nanobiotix, announced that a called NBTXR3, the first product from its NanoXray pipeline, had shown positive intermediate results in a pilot clinical trial on patients with advanced soft tissue sarcoma. These results allowed Nanobiotix to finalize and to announce its development plan for the launch of NBTXR3 on the market: with this first indication, advanced , NBTXR3 could be approved in Europe as early as 2016.

The news led to a jump in the company's stock price—and new funding for research at UB.

Nanobiotix got its start in 2003 by licensing two technologies that Levy, PhD, developed with colleagues at the university and Roswell Park Cancer Institute: magnetic nanoparticles for cancer treatment and diagnosis (NanoMag), and laser-activated nanoparticles for cancer treatment (NanoPDT).

UB received company stock as part of the licensing agreement, and sold the shares in February for $1.35 million. In accordance with university policy, the majority will return to UB, to be reinvested in research.

"This is a real success story," said UB Vice Provost Robert Genco, who oversees the Office of Science, Technology Transfer and Economic Outreach (STOR). The office helps commercialize UB discoveries, in part by handling patent applications and licensing negotiations for technologies developed at the university.

"Nanobiotix is an example of how UB is benefiting society: As a postdoctoral researcher here, Laurent saw the medical and commercial potential of the work he was doing and decided that he wanted to take it further," Genco said. "We're a global university, and we're seeding companies not only in Western New York, but around the world."

At UB, Levy conducted postdoctoral research with SUNY Distinguished Professor Paras Prasad, executive director of the Institute of Laser, Photonics and Biophotonics (ILPB) at UB. Prasad, PhD, is one of the world's pre-eminent thinkers in nanomedicine, which uses super-small particles, materials and devices to treat and diagnose disease.

In the 1990s, when Levy was in Buffalo, the nanomedicine field was just emerging. He joined Prasad's lab, where he developed the idea of using the unique properties of nanoparticles to kill cancer cells.

"It was an exciting field with a lot of great potential; at this time, it was very new, and everything needed to be done," Levy remembers. "I moved to UB because of Dr. Prasad, who proposed to me to develop my ideas in his lab. What I found there was a great place with diverse expertise in biology, physics, chemistry and medicine. This environment was quite unique 15 years ago, and clearly helped me in developing those concepts."

Since leaving UB, Levy has devoted more than a decade to growing Nanobiotix.

The company got its start by licensing the NanoMag and NanoPDT technologies he co-invented at UB, and has since gone on to develop new product lines including NanoXray—nanoparticles that enable doctors to increase the radiotherapy dose in tumors without increasing damage to surrounding healthy tissue.

The company's promise has driven investor interest, with the firm listed on the NYSE Euronext market in 2012 after an initial public offering raised gross proceeds of 14.2 million euros (about $18.1 million) and a capital increase completed in March 2014 of 28.1 million euros (about $38.5 million). The company now has a current market value of over $300 million.

"In the 1990s, Laurent came to our lab with ideas that were extremely forward-thinking for that time," said Prasad, a professor of chemistry, physics, medicine and electrical engineering. "It has been extremely gratifying to be able to help him move those ideas forward in a way that could offer significant benefits to society."

Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Explore further: Medical acoustics, UB reaching COPD patients with new Lung Flute

Related Stories

Medical acoustics, UB reaching COPD patients with new Lung Flute

September 7, 2011
An easy-to-use device developed by a local biomedical company is providing relief to Buffalo-area patients suffering from chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema.

Nanomedicine: Quantum dots appear safe in pioneering study on primates

May 20, 2012
A pioneering study to gauge the toxicity of quantum dots in primates has found the tiny crystals to be safe over a one-year period, a hopeful outcome for doctors and scientists seeking new ways to battle diseases like cancer ...

Novel treatment for gonorrhea acts like a 'live vaccine,' prevents reinfection

September 18, 2013
A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.